AR068756A1 - Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c - Google Patents
Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis cInfo
- Publication number
- AR068756A1 AR068756A1 ARP080104396A ARP080104396A AR068756A1 AR 068756 A1 AR068756 A1 AR 068756A1 AR P080104396 A ARP080104396 A AR P080104396A AR P080104396 A ARP080104396 A AR P080104396A AR 068756 A1 AR068756 A1 AR 068756A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- independently selected
- group
- hydrogen
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- -1 hydroxy C1-4 alkyl Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1) y las sales farmacéuticamente aceptables y estereoisomeros del mismo; en donde: X está ausente o se selecciona a partir de NR5a u oxígeno; i y k son enteros independientemente seleccionados a partir del grupo que consiste en 0, 1, 2, 3 y 4; j es un entero seleccionado a partir del grupo que consiste en 1, 2, 3 y 4, en donde la suma de i + j + k es menor o igual a 5 y mayor o igual a 2 cuando X está ausente, y la suma de i + j + k es menor o igual a 4 y mayor o igual a 1 cuando X es oxígeno; p es 0, 1, 2 o 3; E es OH, NH2, N(H)-alquilo C1-4, N(H)-cicloalquilo C3-6, -C(O)NH- o -N(H)S(O)2-; R1 está ausente, o es hidrogeno, alquilo C1-4, o cicloalquilo C3-6; R2 es alquilo C1-4, halo-alquilo C1-4, o cicloalquilo C3-6-alquilo C0-2; R2a es hidrogeno, alquilo C1-4, halo-alquilo C1-4, o cicloalquilo C3-6-alquilo C0-2; o R2 y R2a, tomados en combinacion, forman un anillo saturado de tres a siete miembros que comprende cero o un átomo de nitrogeno, oxígeno, o azufre del anillo, cuyo anillo está sustituido con cero, uno o dos sustituyentes seleccionados independientemente a partir de alquilo C1-4 y alquenilo C2-4; R3 y R4 se seleccionan independientemente a partir del grupo que consiste en alquilo C1-6, cicloalquilo C4-7, y cicloalquilo C4-7 sustituido con un residuo de alquilo C1-4; R5 representa de cero a tres residuos, cada uno independientemente seleccionado, en cada presentacion, a partir del grupo que consiste en halogeno, hidroxilo, amino, alquilo C1-4, cicloalquilo C3-6, alcoxilo C1-4, mono- y di-alquilo C1-4-amino, hidroxi-alquilo C1-4, y alcoxilo C1-4-alquilo C1-4; R5a se selecciona independientemente en cada presentacion, a partir del grupo que consiste en hidrogeno, alquilo C1-4, halo-alquilo C1-4, cicloalquilo C3-6, hidroxi-alquilo C1-4, y alcoxilo C1-4-alquilo C1-4; y R6 y R7 se seleccionan independientemente a partir de hidrogeno y alquilo C1-4. Reivindicacion 27: Un método para el tratamiento de un trastorno asociado con el virus de hepatitis C, el cual comprende administrar a un sujeto que lo necesite, una cantidad farmacéuticamente aceptable de un compuesto de la reivindicacion 1 o de la reivindicacion 6, de tal manera que se trate el trastorno asociado con el virus de hepatitis C.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97897407P | 2007-10-10 | 2007-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068756A1 true AR068756A1 (es) | 2009-12-02 |
Family
ID=40243948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104396A AR068756A1 (es) | 2007-10-10 | 2008-10-08 | Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8008263B2 (es) |
| EP (1) | EP2205584A1 (es) |
| JP (1) | JP5095824B2 (es) |
| KR (2) | KR101218882B1 (es) |
| CN (2) | CN104016970A (es) |
| AR (1) | AR068756A1 (es) |
| AU (1) | AU2008309589B2 (es) |
| BR (1) | BRPI0817881A2 (es) |
| CA (1) | CA2702132A1 (es) |
| CL (1) | CL2008002995A1 (es) |
| CO (1) | CO6270317A2 (es) |
| CR (1) | CR11310A (es) |
| EA (1) | EA020951B1 (es) |
| MA (1) | MA31767B1 (es) |
| MX (1) | MX2010003916A (es) |
| PE (1) | PE20091237A1 (es) |
| TN (1) | TN2010000137A1 (es) |
| TW (1) | TW200932737A (es) |
| WO (1) | WO2009047264A1 (es) |
| ZA (1) | ZA201001585B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0710878A2 (pt) * | 2006-04-11 | 2015-03-31 | Novartis Ag | Compostos orgânicos e seus usos |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| RU2515318C2 (ru) | 2007-12-21 | 2014-05-10 | Авила Терапьютикс, Инк. | Ингибиторы протеазы вируса гепатита с и их применение |
| RU2523790C2 (ru) | 2007-12-21 | 2014-07-27 | Авила Терапьютикс, Инк. | Ингибиторы протеазы вируса гепатита с и их применение |
| AP2011005695A0 (en) * | 2008-10-15 | 2011-06-30 | Intermune Inc | Therapeutic antiviral poptides. |
| US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8512690B2 (en) * | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| KR20130026410A (en) * | 2009-09-28 | 2013-03-13 | Intermune Inc | Cyclic peptide inhibitors of hepatitis c virus replication |
| TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
| AU2011311880B2 (en) * | 2010-10-08 | 2014-07-24 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| NZ628515A (en) | 2012-02-10 | 2016-06-24 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
| CN103420991B (zh) * | 2012-05-17 | 2017-07-07 | 乳源东阳光药业有限公司 | 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用 |
| TW201408669A (zh) | 2012-08-08 | 2014-03-01 | Merck Sharp & Dohme | Ｈｃｖ ｎｓ３蛋白酶抑制劑 |
| TW201412709A (zh) * | 2012-09-28 | 2014-04-01 | Sunshine Lake Pharma Co Ltd | 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用 |
| SG11201502802PA (en) | 2012-10-19 | 2015-05-28 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN103848819B (zh) * | 2012-11-29 | 2017-04-12 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们在药物中的应用 |
| TWI585082B (zh) * | 2012-11-29 | 2017-06-01 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們的用途 |
| WO2014082380A1 (en) | 2012-11-29 | 2014-06-05 | Sunshine Lake Pharma Co., Ltd. | Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
| CN105164148A (zh) | 2013-03-07 | 2015-12-16 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| US10201614B2 (en) | 2013-03-15 | 2019-02-12 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| EP3086815B1 (en) | 2013-12-27 | 2022-02-09 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
| BR112016015105A8 (pt) | 2013-12-27 | 2018-04-24 | Var2 Pharmaceuticals Aps | conjugados var2csa-droga |
| WO2015110048A1 (en) | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
| US10450378B2 (en) | 2014-09-17 | 2019-10-22 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| CN111433210A (zh) | 2017-12-20 | 2020-07-17 | 诺华股份有限公司 | 作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物 |
| IL302990A (en) | 2020-11-23 | 2023-07-01 | Enanta Pharm Inc | Novel spiropyrrolidine derived antiviral agents |
| US12540141B2 (en) | 2020-11-23 | 2026-02-03 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US20240051950A1 (en) * | 2020-12-22 | 2024-02-15 | The Regents Of The University Of California | Novel CYP3A4-Specific Inhibitors and Methods of Using Same |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| WO2023003610A1 (en) * | 2021-07-23 | 2023-01-26 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| WO2023107419A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| WO2023107417A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Heterocyclic antiviral agents |
| WO2023196307A1 (en) | 2022-04-05 | 2023-10-12 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102206247B (zh) * | 2000-07-21 | 2013-03-27 | 默沙东公司 | 一种具有HCV NS3/NS4a蛋白酶抑制活性的化合物 |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| EP1467989B1 (en) | 2002-01-23 | 2009-09-23 | Schering Corporation | Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatitis c virus infection |
| EP1633711B1 (en) * | 2003-06-17 | 2010-11-24 | Schering Corporation | Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof |
| US7449447B2 (en) * | 2003-08-26 | 2008-11-11 | Schering Corporation | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus |
| AR045596A1 (es) * | 2003-09-05 | 2005-11-02 | Vertex Pharma | Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc |
| AU2004274468B2 (en) * | 2003-09-18 | 2009-07-23 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| ATE416789T1 (de) * | 2003-10-27 | 2008-12-15 | Vertex Pharma | Kombinationen für die hcv-behandlung |
| RU2006124594A (ru) * | 2003-12-11 | 2008-01-27 | Шеринг Корпорейшн (US) | Ингибиторы сериновой протеазы ns3/ns4а вируса гепатита с |
| EP1711515A2 (en) * | 2004-02-04 | 2006-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| US7635694B2 (en) * | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
| JP4874227B2 (ja) * | 2004-02-27 | 2012-02-15 | シェーリング コーポレイション | Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼインヒビターとしての環状ｐ４’ｓを有する新規ケトアミド |
| US7192957B2 (en) * | 2004-02-27 | 2007-03-20 | Schering Corporation | Compounds as inhibitors of hepatitis C virus NS3 serine protease |
| US7205330B2 (en) * | 2004-02-27 | 2007-04-17 | Schering Corporation | Inhibitors of hepatitis C virus NS3 protease |
| DE602005021760D1 (de) * | 2004-02-27 | 2010-07-22 | Schering Corp | Schwefelverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
| EP1737821B1 (en) * | 2004-02-27 | 2009-08-05 | Schering Corporation | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease |
| PE20060309A1 (es) * | 2004-05-06 | 2006-04-13 | Schering Corp | (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l |
| JP2008501802A (ja) * | 2004-06-08 | 2008-01-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 医薬組成物 |
| MX2007002371A (es) * | 2004-08-27 | 2007-04-23 | Schering Corp | Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
| AU2005286727A1 (en) * | 2004-09-23 | 2006-03-30 | Wyeth | Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus |
| EP1804821A4 (en) * | 2004-10-01 | 2009-07-15 | Vertex Pharma | INHIBITION OF HCV NS3-NS4A PROTEASE |
| MY141025A (en) * | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
| AU2006252519B2 (en) * | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
| US20060276404A1 (en) * | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
| US20070021351A1 (en) * | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| WO2006130626A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
| US20070004635A1 (en) * | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
| US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| EP2256113A1 (en) * | 2005-08-02 | 2010-12-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| WO2007120595A2 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Amines for the treatment of hcv |
| BRPI0710153A2 (pt) * | 2006-04-11 | 2011-08-02 | Novartis Ag | compostos orgánicos e seus usos |
| BRPI0710878A2 (pt) * | 2006-04-11 | 2015-03-31 | Novartis Ag | Compostos orgânicos e seus usos |
| MX2008013125A (es) * | 2006-04-11 | 2008-10-21 | Novartis Ag | Compuestos organicos y sus usos. |
| WO2008059367A1 (en) | 2006-11-14 | 2008-05-22 | Pfizer Products Inc. | Penem prodrugs |
| CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
| US8030354B2 (en) | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
| UA100527C2 (en) | 2007-10-10 | 2013-01-10 | Астразенека Аб | Benzothiazoles as ghrelin receptor modulators |
| CA2702171A1 (en) | 2007-10-10 | 2009-04-16 | Takeda Pharmaceutical Company Limited | Amide compound |
-
2008
- 2008-10-08 KR KR1020107007789A patent/KR101218882B1/ko not_active Expired - Fee Related
- 2008-10-08 AR ARP080104396A patent/AR068756A1/es not_active Application Discontinuation
- 2008-10-08 WO PCT/EP2008/063460 patent/WO2009047264A1/en not_active Ceased
- 2008-10-08 EA EA201000556A patent/EA020951B1/ru not_active IP Right Cessation
- 2008-10-08 EP EP08805142A patent/EP2205584A1/en not_active Withdrawn
- 2008-10-08 CA CA2702132A patent/CA2702132A1/en not_active Abandoned
- 2008-10-08 MX MX2010003916A patent/MX2010003916A/es active IP Right Grant
- 2008-10-08 JP JP2010528385A patent/JP5095824B2/ja not_active Expired - Fee Related
- 2008-10-08 KR KR1020127015695A patent/KR101396696B1/ko not_active Expired - Fee Related
- 2008-10-08 BR BRPI0817881 patent/BRPI0817881A2/pt not_active IP Right Cessation
- 2008-10-08 CN CN201410273335.0A patent/CN104016970A/zh active Pending
- 2008-10-08 AU AU2008309589A patent/AU2008309589B2/en not_active Ceased
- 2008-10-08 CN CN200880110944.7A patent/CN101868452B/zh not_active Expired - Fee Related
- 2008-10-09 CL CL2008002995A patent/CL2008002995A1/es unknown
- 2008-10-09 PE PE2008001744A patent/PE20091237A1/es not_active Application Discontinuation
- 2008-10-09 TW TW097139071A patent/TW200932737A/zh unknown
- 2008-10-10 US US12/249,186 patent/US8008263B2/en not_active Expired - Fee Related
-
2010
- 2010-03-04 ZA ZA2010/01585A patent/ZA201001585B/en unknown
- 2010-03-11 CR CR11310A patent/CR11310A/es not_active Application Discontinuation
- 2010-03-26 TN TNP2010000137A patent/TN2010000137A1/fr unknown
- 2010-04-08 MA MA32757A patent/MA31767B1/fr unknown
- 2010-04-30 CO CO10051497A patent/CO6270317A2/es not_active Application Discontinuation
-
2011
- 2011-07-19 US US13/185,683 patent/US8222425B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010003916A (es) | 2010-05-05 |
| US20110275819A1 (en) | 2011-11-10 |
| EP2205584A1 (en) | 2010-07-14 |
| EA020951B1 (ru) | 2015-03-31 |
| KR20120094049A (ko) | 2012-08-23 |
| JP2011500528A (ja) | 2011-01-06 |
| TN2010000137A1 (en) | 2011-09-26 |
| CL2008002995A1 (es) | 2009-06-26 |
| KR20100051749A (ko) | 2010-05-17 |
| EA201000556A1 (ru) | 2010-10-29 |
| BRPI0817881A2 (pt) | 2015-03-31 |
| KR101396696B1 (ko) | 2014-05-16 |
| ZA201001585B (en) | 2010-12-29 |
| KR101218882B1 (ko) | 2013-01-07 |
| CA2702132A1 (en) | 2009-04-16 |
| CN104016970A (zh) | 2014-09-03 |
| US8008263B2 (en) | 2011-08-30 |
| MA31767B1 (fr) | 2010-10-01 |
| TW200932737A (en) | 2009-08-01 |
| JP5095824B2 (ja) | 2012-12-12 |
| PE20091237A1 (es) | 2009-09-14 |
| AU2008309589A1 (en) | 2009-04-16 |
| CR11310A (es) | 2010-05-06 |
| CN101868452B (zh) | 2014-08-06 |
| CN101868452A (zh) | 2010-10-20 |
| WO2009047264A1 (en) | 2009-04-16 |
| CO6270317A2 (es) | 2011-04-20 |
| AU2008309589B2 (en) | 2012-07-05 |
| US8222425B2 (en) | 2012-07-17 |
| US20090137495A1 (en) | 2009-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068756A1 (es) | Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| AR072162A1 (es) | Compuestos de ester boronato y composiciones farmaceuticas de los mismos | |
| CO6531469A2 (es) | Derivados de purina o deazapurina utiles para el tratamiento de (entre otros) infecciones virales | |
| UY28578A1 (es) | Derivados de amida | |
| EA201490726A1 (ru) | Фармацевтические соединения для применения в терапии инфекции clostridium difficile | |
| AR067475A1 (es) | Antagonistas no basico s del receptor de la hormona concentradora de melanina 1 | |
| AR061238A1 (es) | Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c | |
| CO6160288A2 (es) | Composiciones farmaceuticas que comprenden nilotinib o su sal | |
| AR085893A1 (es) | Pirrolopirazina-amidas de piperidina espirociclica como moduladores de los canales ionicos | |
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
| AR047382A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| GEP20125548B (en) | New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| UY29301A1 (es) | Derivados amida | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| AR072880A1 (es) | Derivados nitrogenados de la pancratistatina | |
| RU2013143800A (ru) | Новое производное оксазолидиона и включающая его фармацевтическая композиция | |
| AR047606A1 (es) | 4-oxobenzonitrilos como moduladores de receptores de androgenos,composiciones farmaceuticas que los contienen y usos | |
| RU2015115430A (ru) | Стабилизированные водные композиции нейромышечных блокаторов | |
| AR075251A1 (es) | Derivados de 6-(6-sustituido-triazolopiridazina-sulfanil)-5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles, metodo de preparacion e intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del cancer y otros trastorno hiperproliferativos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |